Business
Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial Officer
Oslo, Norway, 28 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of cancer, today announced the appointment of Geir Christian Melen as new Chief Financial Officer, effective 01 January 2026. Hans Vassgård Eid will be stepping down as CFO of Zelluna ASA from the end of December 2025 and supporting the transition thereafter. “I am very pleased to appoint Geir Christian as our new Chi
About this update from Zelluna Asa
[{"type":"image","alt":"Zelluna ASA","displaySize":"","headline":null,"caption":"Zelluna ASA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C3Qdgv86SfCXtr_6x5fSRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69","width":300,"height":106}},"lazy":false},{"type":"text","content":"Oslo, Norway, 28 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of cancer, today announced the appointment of Geir Christian Melen as new Chief Financial Officer, effective 01 January 2026. Hans Vassgård Eid will be stepping down as CFO of Zelluna ASA from the end of December 2025 and supporting the transition thereafter.","length":440,"tagName":"p"},{"type":"text","content":"“I am very pleased to appoint Geir Christian as our new Chief Financial Officer at such a pivotal time for Zelluna. After seven years with the company, Geir brings a deep understanding of our TCR-NK platform and a strong financial skill set that will support our transition into clinical development. I would also like to express my sincere appreciation to Hans for his significant contributions to Zelluna. He has been CFO of Ultimovacs since 2015 and played a key role in securing a successful business combination between Zelluna and Ultimovacs. I am grateful for his strong contributions successfully integrating the two businesses, and creating a sound basis for taking Zelluna into the clinical development phase. We wish him every success in his future endeavours.” said Namir Hassan, CEO of Zelluna","length":806,"tagName":"p"},{"type":"text","content":"Geir Christian brings extensive senior leadership experience across the Norwegian biotech and life sciences sector, including multiple CFO and CEO roles in both publicly listed and privately held companies including in Algeta and Photocure. Over his career, he has led financial operations, corporate strategy, and capital market engagement for several life science organisations, giving him a deep understanding of the financial, regulatory, and operational demands of the industry.","length":483,...